Biotechnology
Manufacturing
Health

Biogen

$282.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$8.76 (+3.20%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Biogen and other stocks, options, ETFs, and crypto commission-free!

About BIIB

Biogen Inc. Common Stock, also called Biogen, is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Read More It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. The listed name for BIIB is Biogen Inc. Common Stock.

CEO
Michel Vounatsos
Employees
7,400
Headquarters
Cambridge, Massachusetts
Founded
1978
Market Cap
44.65B
Price-Earnings Ratio
8.01
Dividend Yield
—
Average Volume
1.39M
High Today
$287.88
Low Today
$279.18
Open Price
$279.94
Volume
1.78M
52 Week High
$374.99
52 Week Low
$219.70

Collections

Biotechnology
Manufacturing
Health
Therapy
Technology
US
North America

BIIB News

Reuters9h

Merck, Pfizer prevail in patent fight with Biogen over multiple sclerosis drug

A federal appeals court on Monday invalidated a Biogen Inc patent on the treatment of multiple sclerosis using a protein known as interferon-beta, a victory for

BIIB Earnings

$0.00
$3.42
$6.84
$10.26
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Oct 20, Pre-Market

You May Also Like

GPP
SLMBP
NRGZ
GLEO+
CLNY-B
SFST
NHF
FFNW
PDCO
KDP
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.
Buy BIIB
Commissions
$0.00
Est. Quantity
0
Sign up for a Robinhood Account to buy or sell Biogen stock and options commission-free.
LearnBlogCareersHelpLog InSign Up